iBio, Inc. filings document material events for an AI-driven biotechnology company developing precision antibody therapies. Recent Form 8-K disclosures cover clinical and regulatory updates for IBIO-600, preclinical data for IBIO-610, quarterly financial results, Regulation FD communications and other pipeline-related events.
The company's filings also record capital-structure matters involving common stock, pre-funded warrants and Series G warrants, along with shareholder voting results, board composition, committee appointments and governance items disclosed through annual-meeting and material-event reports.
iBio, Inc. reported a larger net loss while significantly strengthening its balance sheet as it advances its AI-driven obesity pipeline. For the three months ended December 31, 2025, the company generated no revenue, versus $200,000 a year earlier, and posted a net loss of $8.99 million as research and development and general and administrative expenses more than doubled.
For the six-month period, revenue was $100,000 and the net loss widened to $14.71 million. Operating cash outflows were $10.91 million, but financing activities, including sales of pre-funded warrants and common stock, provided $55.49 million, lifting cash and cash equivalents to $28.67 million and investments in debt securities to $24.03 million as of December 31, 2025.
The company recorded a $2.5 million impairment on an oncology intangible asset as it sharpened its focus on cardiometabolic and obesity antibodies. With approximately $52.7 million in cash and investments at period end and an additional $26 million raised in a January 2026 private placement, iBio believes it can fund operations for at least 12 months as it prepares IBIO-600 for Phase 1a trials in the first half of 2026 and targets first-in-human studies for IBIO-610 in early 2027.
iBio, Inc. reported a larger loss for its fiscal second quarter ended December 31, 2025 while strengthening its balance sheet and advancing its obesity-focused antibody pipeline. The company completed a $26 million private placement led by a biotech investor, receiving net proceeds of approximately $24.4 million in January 2026 and extending its cash runway into the third quarter of fiscal year 2028.
For the quarter, iBio recognized no revenue, compared with $0.2 million a year earlier. Research and development expenses rose to $4.3 million from $1.9 million, driven by higher spending on consultants, outside services, and personnel to progress IBIO-600, IBIO-610 and other preclinical assets. General and administrative expenses increased to approximately $5.2 million from $2.7 million, primarily due to an impairment of the IBIO-101 intangible asset, resulting in a net loss of $8,993 thousand versus $4,364 thousand.
iBio held $52.7 million in cash, cash equivalents and investments in debt securities as of December 31, 2025. Management highlighted initiation of CMC development and toxicology studies for IBIO-610 and IBIO-600 as key steps toward planned human clinical trials.
iBio, Inc. is registering up to 11,061,738 shares of common stock for resale by existing investors, including 1,408,481 already-issued shares and up to 9,653,257 shares underlying pre-funded warrants.
The company will not sell any shares in this offering and will not receive proceeds from stockholder resales, other than any cash paid if pre-funded warrants are exercised at $0.001 per share. These securities stem from a January 2026 private placement that generated approximately $26 million in gross proceeds at prices of $2.35 per share and $2.349 per pre-funded warrant.
iBio is a preclinical-stage biotechnology company using AI-driven antibody discovery to develop cardiometabolic and obesity therapies, with its IBIO-610 program expected to enter first-in-human trials in early 2027. Shares outstanding were 32,540,942 as of January 30, 2026, with 42,194,199 shares assuming full exercise of the pre-funded warrants.
iBio, Inc. is registering 11,061,738 shares of common stock for resale by existing investors following a January 2026 private placement. The shares include 1,408,481 already issued common shares and up to 9,653,257 shares issuable upon exercise of pre-funded warrants with a $0.001 exercise price.
The company previously raised approximately $26 million in gross proceeds in the private placement at a purchase price of $2.35 per common share. iBio will not receive proceeds from resale of these shares, other than nominal amounts if the pre-funded warrants are exercised. The filing fulfills registration rights granted to the investors and may increase potential share sales into the market.
iBio, Inc. reported that its Chief Legal Officer, Marc Banjak, received a grant of stock options on January 28, 2026. The award covers 146,000 stock options with an exercise price of $2.23 per share, all held directly.
According to the vesting terms, 25% of the common stock underlying these options will vest on the one-year anniversary of the grant date. The remaining options will then vest in equal quarterly installments over the following 36 months, so long as Banjak remains employed by iBio.
iBio, Inc. reported that its Chief Financial Officer, Felipe Duran, received a grant of stock options covering 179,000 shares of common stock on January 28, 2026 at an exercise price of $2.23 per share. All 179,000 options were reported as directly owned after the grant.
The options vest over time. 25% of the underlying shares will vest on the one-year anniversary of the grant date, and the remaining options will vest in equal quarterly installments over the following 36 months, as long as Duran remains employed by iBio. The options become exercisable starting January 28, 2027 and are scheduled to expire on January 27, 2036.
iBio, Inc. reported that its Chief Executive Officer and Chief Scientific Officer, Martin Brenner, who also serves as a director, received a grant of stock options. On January 28, 2026, he was awarded 479,000 stock options to purchase common stock at an exercise price of $2.23 per share.
According to the filing, 25% of the underlying shares will vest on the one-year anniversary of the grant date. The remaining 75% will vest in equal quarterly installments over the following 36 months, as long as Brenner remains employed by iBio. After this grant, he beneficially owns 479,000 stock options directly.
Affinity Asset Advisors, LLC and Michael Cho report a 9.99% beneficial stake in iBio, Inc. common stock. They collectively report control over 2,401,616 shares, including 144,416 shares issuable upon exercise of warrants.
The securities are held through Affinity Healthcare Fund, LP, for which Affinity Asset Advisors acts as investment manager. The warrants are subject to a 9.99% beneficial ownership limitation, and the position is certified as being held in the ordinary course of business, not to influence control of iBio.
iBio, Inc. received a Schedule 13G filing from several Millennium-affiliated investment entities and Israel A. Englander disclosing a new passive ownership position. Integrated Core Strategies (US) LLC reports beneficial ownership of 1,234,295 shares of iBio common stock, while Millennium Management LLC, Millennium Group Management LLC and Mr. Englander each report 1,235,827 shares, representing 5.2% of the outstanding common stock in each case.
The ownership percentage is based on 23,895,789 iBio shares outstanding, combining 22,487,308 shares reported in a prior Form 10‑Q/A and 1,408,481 shares issued in a recent private placement. The reporting persons certify the shares were not acquired and are not held for the purpose of changing or influencing control of iBio, and they entered into a joint filing agreement to report this position together.